Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia

Norbert VeyDepartment of Hematology, Institut Paoli Calmettes, SIRIC-Marseille, Marseille, France; ;Aix-Marseille University, Marseille, France; Correspondence[email protected]

Thomas PrebetInternal Medicine Department, Section of Hematology, Yale Cancer Center at Yale University, New Haven, CT, USA;

http://orcid.org/0000-0002-6872-625X

Claire ThalamasDepartment of Medical Pharmacology, CIC 1436, Université Toulouse Hospital, Inserm, Toulouse, France;

Aude CharbonnierDepartment of Hematology, Institut Paoli Calmettes, SIRIC-Marseille, Marseille, France;

Jerome ReyDepartment of Hematology, Institut Paoli Calmettes, SIRIC-Marseille, Marseille, France;

Ioana KloosDepartment of Oncology Research and Development, Institut de Recherches Internationales Servier, Suresnes, France;

Emily LiuBiometrics, Pharmacyclics, LLC, an AbbVie Company, Sunnyvale, CA, USA;

Ying LuanBiometrics, Pharmacyclics, LLC, an AbbVie Company, Sunnyvale, CA, USA;

Remus VezanDepartment of Clinical Science, Pharmacyclics, LLC, an AbbVie Company, Sunnyvale, CA, USA;

Thorsten GraefDepartment of Clinical Science, Pharmacyclics, LLC, an AbbVie Company, Sunnyvale, CA, USA;

Christian RecherService d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; ;Cancer Research Center of Toulouse, UMR1037-INSERM, ERL5294-CNRS, Toulouse, France

show all

Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia

Table 1. Baseline characteristics.

Table 2. Patient disposition.

Table 3. Pharmacokinetic parameters for abexinostat.

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Supplemental Figure

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia

Figures & data

Table 1. Baseline characteristics.

Table 2. Patient disposition.

Table 3. Pharmacokinetic parameters for abexinostat.

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Supplemental Figure

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date